ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Behavioral deficits after traumatic brain injury: Neuroprotective effect of Diosmin.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following traumatic brain injury (TBI), the progression of brain tissue injuries and subsequent psychiatric complications considerably affect the quality of life in humans. Diosmin (DM) is a flavonoid and has been demonstrated to improve cognitive deficit and amplify brain electrical activity in the rat model of traumatic brain injury. We aimed to explore the potential protective effects of DM on single-unit neuronal firing, as well as on motor function and behaviors related to depression and anxiety associated with TBI. Forty-eight Wistar rats were randomly divided into sham-operated, TBI, and TBI + DM (100 mg/kg/day; P.O.) Groups. Depression and anxiety-like behaviors and motor function were evaluated through standard behavioral tests and Rotarod apparatus at scheduled points in time. We also measured the neuronal firing rate in the striatum. The results indicated that DM pretreatment significantly improved TBI-induced depression and anxiety-like behaviors (P < 0.01), and motor coordination (P < 0.05). The striatum neuronal firing rate in the TBI + DM Group was significantly higher than the TBI group (216 Vs 49.38 Hz, P < 0.001). The findings suggest that pretreatment with DM may offer protective benefits against TBI-associated behavioral deficits.
Indexed as
Identifiers
40261347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.